ClinicalTrials.gg

Macular Edema clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 758 studies for Macular Edema across more than 10 countries. 65 are recruiting or about to start. 557 of them are mainly about Macular Edema (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 1,117 studies for Macular Edema. How that becomes 755 here

This page counts the studies the registry files under Macular Edema, and those it files under no condition that list Macular Edemathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,117Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −198List Macular Edema as a condition, but the registry did not file them under itMost often written as “Diabetic Macular Edema” (155), “Diabetic Macular Edema (DME)” (22), and “Central Retinal Vein Occlusion With Macular Edema” (5). The registry filed them under other conditions only, most often Diabetic Retinopathy (98) and Macular Degeneration (39).
  3. −164Match it another way108 name it in the title, 23 in a keyword, and 33 by a synonym or other text the search reads.
  4. 755The count on this page337 of them list Macular Edema in their own words; the registry filed them under no condition.

Status

Completed
471
Status unknown
103
Terminated
60
Recruiting
43
Withdrawn
31
Active, not recruiting
27

Phase

Phase 2
197
Phase 3
157
Phase 4
127
Phase 1
108
Early Phase 1
5

Where

United States
276
China
72
Germany
66
France
56
Canada
53
United Kingdom
51

Who develops what

Add Macular Edema to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 21 programs from 15 companies, 20 with this as their studies’ main aim; 9 with a live phase 3 study; 11 primary completions in the next 12 months. Compare Hoffmann-La Roche, Boehringer Ingelheim and Merck here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
afliberceptRecent, repeated
Evidence
  • NCT07705607 · Merck & Co., Inc · Phase 3 · live · comparator · “Aflibercept” · registered Jul 2026
  • NCT07705555 · Merck & Co., Inc · Phase 3 · live · comparator · “Aflibercept” · registered Jul 2026
  • NCT07734844 · Kodiak Sciences Inc · Phase 3 · live · comparator · “Aflibercept (2.0 mg)” · registered May 2026
  • NCT07489131 · Alvotech Swiss AG · Phase 3 · live · comparator · “Eylea HD (aflibercept HD)” · registered Mar 2026
  • NCT07449923 · EyePoint Pharmaceuticals, Inc. · Phase 3 · live · comparator · “Aflibercept (2.0 mg)” · registered Feb 2026
Regeneron Pharmaceuticals28% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2011) + 5 othersEU: Bayer (EMA 2012) + 12 others912 studies
RanibizumabRecent, repeated
Evidence
  • NCT07515079 · Bio-Thera Solutions · Phase 3 · live · comparator · “Lucentis” · registered Mar 2026
  • NCT06957080 · Merck & Co., Inc · Phase 3 · live · comparator · “Ranibizumab” · registered Apr 2025
  • NCT06571045 · Merck & Co., Inc · Phase 3 · live · comparator · “Ranibizumab” · registered Aug 2024
  • NCT06305416 · incepta pharmaceuticals ltd · Phase 3 · comparator · “Lucentis” · registered Mar 2024
  • NCT05520177 · 3SBio Inc. · Phase 3 · comparator · “ranibizumab 0.5mg” · registered Aug 2022
Novartis52% of its industry studiesUS: Hoffmann-La Roche (FDA 2006) + 3 othersEU: Novartis (EMA 2007) + 9 others68 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
remigromig☆ Track2 live phase-3 studies: NCT06571045, NCT06957080Merck & Co., Inc
KSI-101☆ Track2 live phase-3 studies: NCT06996080, NCT06990399Kodiak Sciences Inc
BAT5906☆ Track1 live phase-3 study: NCT07515079Bio-Thera Solutions
SMO1☆ Track1 live phase-3 study: NCT07708142SANGMYUNG innovation
AVT29☆ Track1 live phase-3 study: NCT07489131Alvotech Swiss AG

The 5 in phase 3 with the nearest primary completion, of 21 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (11)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.KIO-104 · Kiora Pharmaceuticals, Inc. · Phase 2 main aimNCT06825702 Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema — primary endpoint: Safety and Tolerability · 28 enrolled
  • Nov 2026 est.SNP318 · SciNeuro · Phase 2 main aimNCT07199777 A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients — primary endpoint: Safety Events · 60 enrolled
  • 11 Jan 2027 est.remigromig · Merck & Co., Inc · Phase 3 main aimvs RanibizumabNCT06957080 A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME — primary endpoint: Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart · 1,054 enrolled

8 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Macular Edema studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 3 open · Angiogenesis inhibitors 1 open · NSAIDs 1 open

Coming up

36studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger. 1 (2%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (5%) take healthy volunteers.

Recruiting studies that take each age, of 43
AgeWomenMen
100 (0%)0 (0%)
1836 (84%)36 (84%)
3039 (91%)39 (91%)
4042 (98%)42 (98%)
5042 (98%)42 (98%)
6542 (98%)42 (98%)
7536 (84%)36 (84%)
8534 (79%)34 (79%)

Across all 758 studies, recruiting or not: 6% stop at 75 or younger and 2% at 65; 9% take children; <1% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Macular Edema studies take

Of 65 phase 3 interventional studies under Macular Edema, half reached primary completion within 25 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 124 mo11–51 · 25 studies——
Phase 1/246 mo23–68 · 16 studies——
Phase 219 mo15–32 · 50 studies18 mo14–28 · 32 studies—
Phase 325 mo18–38 · 65 studies24 mo18–33 · 52 studies—
Phase 426 mo15–43 · 63 studies—28 mo15–43 · 51 studies
Interventional, no phase18 mo8–37 · 51 studies—21 mo8–42 · 47 studies
Observational25 mo12–52 · 44 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 758. Browse all 758 → or search them.